Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

371
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
371

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel NAMPT activator ameliorates obesity by repressing ACSL1-dependent lipid synthesis.

Acta pharmaceutica Sinica. B·2026
Same author

A multicenter retrospective analysis of canine idiopathic epilepsy in China.

Frontiers in veterinary science·2026
Same author

Functionalized Fluorescent Nanodiamonds Reveal Therapeutic Protein Clearance Through ENDOTAC Linked to AUTOTAC.

Advanced healthcare materials·2026
Same author

Assessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs.

The oncologist·2026
Same author

A glimpse into the future of model-informed drug discovery and development.

Advanced drug delivery reviews·2026
Same author

Individualized Prediction of Radiation Pneumonitis Using RP-GAN: Leveraging Global Lung Features and Explainable Artificial Intelligence.

Technology in cancer research & treatment·2026

Related Experiment Video

Updated: Jul 3, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K

Pediatric oncology drug development and dosage optimization.

S Y Amy Cheung1, Justin L Hay1, Yu-Wei Lin1

  • 1Certara, Princeton, NJ, United States.

Frontiers in Oncology
|February 13, 2024
PubMed
Summary

Optimizing pediatric oncology drug dosage is crucial due to challenges in traditional methods. Quantitative approaches like pharmacometrics can help find optimal doses, accelerating development for children.

Keywords:
Project Optimusclinical trial designdosage optimizationmodel informed drug developmentmodeling and simulationoncologypediatric

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

10.9K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

Related Experiment Videos

Last Updated: Jul 3, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.3K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

10.9K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

Area of Science:

  • Oncology
  • Pediatric Pharmacology
  • Drug Development

Background:

  • Oncology drug development faces significant challenges, particularly in pediatric studies.
  • Pediatric drug dosing often lags adult development, using body size scaling from adult doses.
  • Traditional dose escalation to maximum tolerated dose (MTD) may not be optimal, especially for combination therapies and long-term safety.

Purpose of the Study:

  • To review the regulatory landscape and incentives impacting pediatric oncology drug discovery.
  • To discuss challenges and opportunities in pediatric cancer clinical trial design.
  • To explore the role of quantitative methods, like pharmacometrics, in pediatric dosage-finding.

Main Methods:

  • Review of current regulatory policies and incentives for pediatric drug development.
  • Analysis of challenges specific to pediatric oncology clinical trials.
  • Outline of pharmacometric and modeling & simulation approaches for dosage justification.

Main Results:

  • Traditional MTD determination may be suboptimal; optimal dosing below MTD is critical.
  • Pediatric drug development faces unique hurdles including small patient populations and developmental variations.
  • Quantitative methods offer a promising avenue to support and justify pediatric dosing strategies.

Conclusions:

  • Accelerating pediatric oncology drug discovery requires addressing regulatory, trial design, and dosing challenges.
  • Pharmacometrics and modeling & simulation are vital tools for optimizing pediatric drug dosage.
  • A comprehensive strategy incorporating regulatory insights and advanced quantitative methods is needed to improve pediatric cancer treatment access.